| __timestamp | BioMarin Pharmaceutical Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 176081000 |
| Thursday, January 1, 2015 | 152008000 | 157939000 |
| Friday, January 1, 2016 | 209620000 | 164073000 |
| Sunday, January 1, 2017 | 241786000 | 169243000 |
| Monday, January 1, 2018 | 315264000 | 168489000 |
| Tuesday, January 1, 2019 | 359466000 | 172526000 |
| Wednesday, January 1, 2020 | 524272000 | 200649000 |
| Friday, January 1, 2021 | 470515000 | 237513000 |
| Saturday, January 1, 2022 | 483669000 | 353358000 |
| Sunday, January 1, 2023 | 577065000 | 586886000 |
| Monday, January 1, 2024 | 580235000 |
Data in motion
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. From 2014 to 2023, BioMarin Pharmaceutical Inc. and Lantheus Holdings, Inc. have shown intriguing trends in their cost of revenue. BioMarin's cost of revenue surged by approximately 345%, starting at $130 million in 2014 and peaking at $577 million in 2023. Meanwhile, Lantheus experienced a 233% increase, from $176 million to $587 million over the same period. Notably, 2023 marked a pivotal year where Lantheus surpassed BioMarin, highlighting a significant shift in their financial strategies. This data underscores the importance of strategic cost management in maintaining competitive advantage. As the pharmaceutical industry continues to grow, these insights provide a window into the financial health and operational efficiency of these key players.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Lantheus Holdings, Inc.
Amgen Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Gilead Sciences, Inc. and Lantheus Holdings, Inc.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: BeiGene, Ltd. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs Lantheus Holdings, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: BioMarin Pharmaceutical Inc. vs Wave Life Sciences Ltd.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Galapagos NV
Cost of Revenue: Key Insights for Lantheus Holdings, Inc. and ADMA Biologics, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Wave Life Sciences Ltd.'s Expenses